Weitzman ECHO Substance Use Disorder in Pregnancy (SMART)

Program Information

Women are most likely to develop a substance use disorder during their child bearing years, which is between the ages of 18 and 44 years old. The number of women who self-reported using substances such as heroin, tobacco and alcohol during their pregnancy has been increasing in recent years. It’s crucial that obstetrics and gynecology experts are equipped with the knowledge and skill set to best treat this growing population.

Weitzman ECHO Substance Use Disorder in Pregnancy (also referred to as Project ECHO Support Models for Addiction Related Treatment or SMART), is designed and delivered in collaboration with Yale University, and meets once a month to connect OB/GYNs that have pregnant and postpartum patients with substance use disorders to a team of doctors who have content expertise in the Psychiatry, Perinatal & Childhood mental health, Addiction Medicine, and Prenatal Care.

Weitzman ECHO SMART sessions provide these OB/GYNs the support and expert advice they need to treat their growing panels of pregnant and postpartum patients with a substance use disorder.

This ECHO meets the first Tuesday of every month from 12-1pm ET.

Acknowledgement of Support

Weitzman ECHO Substance Use Disorder in Pregnancy (also referred to as Project ECHO Support Models for Addiction Related Treatment or SMART), is designed and delivered in collaboration with Yale University. Weitzman ECHO SMART is supported by Yale University with funding through the  Patient-Centered Outcomes Research Institute (PCORI).

Target Audience

This activity is appropriate for OB/GYNs.

Registration Information

Weitzman ECHO Substance Use Disorder in Pregnancy (also referred to as Project ECHO Support Models for Addiction Related Treatment or SMART) is currently closed for registration. This ECHO program has been designed and delivered in collaboration with Yale University and is only offered to a specific cohort of OB/GYNs through this partnership. 

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Educate OB/GYNs on the harm reduction model of care. 
  • Explain how to talk to patients about the option of treatment of opioid use disorder in the setting of pregnancy. 
  • Review MAT for opioid use disorder in challenging situations such as severe substance use, relapse and poor adherence. 
  • Provide an understanding of buprenorphine induction, titration and maintenance in the setting of pregnancy.
Activity summary
Available credit: 
  • 6.00 AAPA Category I CME
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide American Academy of PAs (AAPA) credit to physician assistants at its activities. Participants should only claim commensurate credit with the extent of their participation in the activity.
  • 6.00 ACE/ASWB
    Through Joint Accreditation Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide Association of Social Work Boards (ASWB) credit to social workers at its activities.
  • 6.00 ACPE
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide Accreditation Council for Pharmacy Education (ACPE) credit to pharmacists at its activities.
  • 6.00 AMA PRA Category 1 Credit
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide AMA PRA Category 1 Credit™ to physicians at its activities via Accreditation Council for Continuing Medical Education (ACCME).
  • 6.00 ANCC
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide American Nurses Credentialing Center (ANCC) nursing credit to nurses at its activities.
  • 6.00 APA
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide American Psychological Association (APA) credit to psychologists at its activities.
  • 6.00 Participation Hour(s)
    If you are not able to utilize any of the above credit types, you are able to download an unaccredited Participation Certificate for your records.
Activity opens: 
01/01/2022
Activity expires: 
12/31/2022

Schedule

This ECHO meets the first Tuesday of every month from 12-1pm ET. Below are the dates of the remaining sessions: 

  • April 5, 2022
  • May 3, 2022
  • June 7, 2022

Faculty

Amalia Londono-Tobon, MD, is a board-certified psychiatrist subspecializing in perinatal and childhood mental health. Amalia obtained her B.A. in Neuroscience from Johns Hopkins University, her M.D. from Stanford University, and her residency training from Yale University. Throughout her academic career, Amalia has conducted basic and clinical research in neurodevelopment and the treatment of mental health disorders.

Katherine Callaghan, MD, is the founder and director of UMassMemorial’s Karen W Green Clinic for Pregnancy and Recovery. This multidisciplinary clinic provides comprehensive prenatal care and addiction treatment to women with a variety of substance use disorders. “The Green Clinic” seeks to optimize and integrate obstetrical & postpartum care, Medication Assisted Treatment, psychiatric services, Peer Support and social work support to women in recovery, seeking recovery or actively using substances. Since joining the Ob/Gyn Department at UMassMemorial in 2014, Katherine has led a committee of nurses, pharmacists, addiction specialists and administrators in drafting, finalizing and implementing in-patient protocols for initiating Medication Assisted Treatment (MAT) in the pregnant patient, including both a methadone protocol and a buprenorphine protocol. These protocols have both improved and streamlined the process, making MAT a readily available option for pregnant women seeking care. 

David A. Fiellin, MD, is a Professor of Medicine, Emergency Medicine and Public Health at Yale.  He Directs the Yale Program in Addiction Medicine and the Clinical and Health Services Research Core at Yale’s Center for Interdisciplinary Research on AIDS.  He is board certified in Internal Medicine and Addiction Medicine. His NIH-funded research is on the interface between substance use and general medical settings including office-based practice, primary care, Emergency Department and HIV specialty settings. He has received awards from the American Association for the Treatment of Opioid Dependence, the American Society of Addiction Medicine, AMERSA, and the Hazelden Betty Ford Foundation. He is Co-Editor of the ASAM textbook, Principles of Addiction Medicine, 4th, 5th and 6th Editions, and on the Editorial Boards of 4 addiction specialty journals. He has served on the Board of Directors of the College on Problems of Drug Dependence and as Co-Chair of the Substance Abuse Interest Group at the Society of General Internal Medicine.  

Leena Mittal, MD, is the Chief of the Division of Women's Mental Health at Brigham and Women's Hospital and an Instructor in Psychiatry at Harvard Medical School, and serves as the Program Director for the Women's Mental Health Fellowship at the Brigham.  Dr. Mittal has numerous publications and speaks nationally on the treatment of mental health and substance use conditions throughout pregnancy and the postpartum period.  Dr. Mittal is board certified in psychiatry, psychosomatic medicine and addiction medicine.   Additionally, Dr. Mittal is the Associate Medical Director for the Massachusetts Child Psychiatry Access Program for Moms (MCPAP for Moms), an innovative statewide consultation service for providers seeing pregnant and postpartum women with mental health and substance use conditions.  

Ariadna Forray, MD, is an Associate Professor of Psychiatry at Yale School of Medicine. She received her B.A. in neuroscience from Bryn Mawr and her M.D. from Harvard. During her psychiatry residency training at Yale she joined the Neuroscience Research Training Program and studied the impact of pregnancy, PTSD and pregnancy-specific anxiety on stress reactivity and arousal using the affect modulation of the acoustic startle reflex. Following residency, she joined the faculty at Yale and was awarded funding through the competitive Clinician Scientist Training Program (K12), and focused her research on the development of novel treatments for perinatal substance use. As a principal investigator and co-investigator on several NIH-funded grants, she has developed and implemented addiction treatment interventions, successfully recruited pregnant women with substance use disorders for participation in clinical research, and collaborated with researchers and clinicians across disciplines. As part of her clinical work, Dr. Forray is an attending on the Behavioral Intervention Team and the Resident Education Director for the Psychological Medicine Service at Yale New Haven Hospital. She is also the Psychiatry Director of the multidisciplinary Adult Sickle Cell Program.

Weitzman Institute Disclosure Statement

It is the policy of the Weitzman Institute to ensure that Continuing Education (CE) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the Weitzman Institute requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

Faculty participating in a Weitzman Institute-sponsored activity must disclose to the planning committee and audience all financial or other relationship(s) with ineligible companies.

Faculty Disclosures

No faculty disclosed a relevant financial relationship for this program.

Accreditation Statement

In support of improving patient care, Community Health Center, Inc./Weitzman Institute is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credential Center (ANCC) to provide continuing education for the healthcare team.   

Designation Statement

Through Joint Accreditation, Community Health Center, Inc./Weitzman Institute is able to provide AMA PRA Category 1 Credit™ to physicians at its activities via Accreditation Council for Continuing Medical Education (ACCME).

By completing this activity you provide the Weitzman Institute permission to share completion data with the ACCME and the certifying board(s).

Joint Accreditation Logo

Available Credit

  • 6.00 AAPA Category I CME
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide American Academy of PAs (AAPA) credit to physician assistants at its activities. Participants should only claim commensurate credit with the extent of their participation in the activity.
  • 6.00 ACE/ASWB
    Through Joint Accreditation Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide Association of Social Work Boards (ASWB) credit to social workers at its activities.
  • 6.00 ACPE
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide Accreditation Council for Pharmacy Education (ACPE) credit to pharmacists at its activities.
  • 6.00 AMA PRA Category 1 Credit
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide AMA PRA Category 1 Credit™ to physicians at its activities via Accreditation Council for Continuing Medical Education (ACCME).
  • 6.00 ANCC
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide American Nurses Credentialing Center (ANCC) nursing credit to nurses at its activities.
  • 6.00 APA
    Through Joint Accreditation, Moses/Weitzman Health Center, Inc./Weitzman Institute is able to provide American Psychological Association (APA) credit to psychologists at its activities.
  • 6.00 Participation Hour(s)
    If you are not able to utilize any of the above credit types, you are able to download an unaccredited Participation Certificate for your records.
Please login or register to take this activity.

Weitzman ECHO Substance Use Disorder in Pregnancy (also referred to as Project ECHO Support Models for Addiction Related Treatment or SMART) is currently closed for registration. This ECHO program has been designed and delivered in collaboration with Yale University and is only offered to a specific cohort of OB/GYNs through this partnership.

Required Hardware/Software

  • This online activity requires use of a device connected to the Internet, such as a computer tablet or mobile device. 
  • The ECHO will take place over Zoom, which must be accessed directly from within the activity.